% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hansen:276325,
      author       = {Hansen, Niels and Teegen, Bianca and Hirschel, Sina and
                      Fox, Janosch and Fitzner, Dirk and Wiltfang, Jens and
                      Bartels, Claudia},
      title        = {{L}ongitudinally persisting {KCNA}2-autoantibodies in mild
                      amnestic dementia with {A}lzheimer´s pathology - {R}eport
                      and literature review.},
      journal      = {Behavioural brain research},
      volume       = {482},
      issn         = {0166-4328},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DZNE-2025-00288},
      pages        = {115437},
      year         = {2025},
      abstract     = {Neural autoantibodies are being increasingly detected in
                      conjunction with neurodegenerative dementias such as
                      Alzheimer's disease dementia (AD), yet their significance is
                      not well clarified. In this case report, we report the
                      previously unreported long-lasting persistence of potassium
                      voltage-gated channel subfamily A member 2 (KCNA2)
                      antibodies in biomarker-supported AD.We report on a
                      77-year-old, male patient evaluated in our outpatient memory
                      clinic of the Department of Psychiatry and Psychotherapy,
                      University Medical Center Göttingen. Neuropsychological
                      test results and autoantibody testing in serum over a period
                      of 4-5 years is provided.Our patient exhibited mild dementia
                      syndrome and was diagnosed with AD on the basis of a
                      prototypical biomarker profile (reduced Aβ42/40 ratio and
                      elevated p-tau181 protein in cerebrospinal fluid). Within a
                      5-year follow-up with regular visits to our memory clinic,
                      we observed a nearly stable neuropsychological profile of
                      mild, amnestic variant dementia that did not noticeably
                      progress. KCNA2 autoantibodies were also detectable in serum
                      over 4 years with increasing titers over time. Combined
                      anti-dementia therapy with donepezil, multimodal therapy
                      including non-pharmacological cognitive therapy, and
                      immunotherapy with intravenous methylprednisolone was
                      carried out as an individual treatment approach.KCNA2
                      autoantibody persistence in biomarker-supported AD does not
                      necessarily trigger a poor outcome in the long-term, as
                      cognitive impairment did not progress subsequently. At the
                      same time, mild immunotherapy did not result in less
                      immunoreactivity in conjunction with the detection of KCNA2
                      autoantibodies. This detection of KCNA2 autoantibodies in AD
                      could provide indices of a potentially benign long-term AD
                      course that should be further evaluated in studies.},
      keywords     = {Alzheimer´s pathology (Other) / Autoimmunity (Other) /
                      Dementia (Other) / KCNA2 autoantibodies (Other)},
      cin          = {AG Wiltfang},
      ddc          = {610},
      cid          = {I:(DE-2719)1410006},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39855473},
      doi          = {10.1016/j.bbr.2025.115437},
      url          = {https://pub.dzne.de/record/276325},
}